Biotech Isn’t One Trade. It’s a Stack.
🧬 Biotech has been running for weeks. It’s not one trade. It’s a stack.
1. The Stack
- 🧬 Gene editing: $BEAM $PRME
- 🤖 AI discovery: $ABCL $RXRX
- 📊 Data + diagnostics: $TEM $GRAL
- 🧪 Synthetic bio: $TWST
- 💊 Commercial: $TGTX $INSM
- 📦 The basket: $ARKG
DATA trains the models. The MODELS pick the molecules. The EDITORS fix the code. COMMERCIAL is where it gets paid.
Since mid-September: an FDA clearance, clinical proof of concept, a regulatory door opening for gene editing, big pharma writing checks, and new 52-week highs.
That’s not a bounce. That’s a re-rate. 👀
2. Why Now
Why are biotechs running? Look at the last six weeks. 🧐
- Sep: FDA clears $PRME to start its in-body prime editing trial for Alpha-1. $TWST hits 52-week highs on its Lilly AI deal. ARK adds gene editing.
- Oct: $TEM clears antitrust for the Personalis deal. Merck KGaA buys Silence at a ~130% premium. Gilead pays $1.275B for a Phase 1 pill.
- Last week: FDA draft guidance lets one application cover many patient-specific gene edits. $BEAM shows proof of concept for BEAM-301. Editors rip.
Catalysts stacking on catalysts.
The cost of failure is falling. The buyers are showing up. The re-rate already started.
3. One-Liner
Everyone’s arguing about whether AI tops. Meanwhile biotech has quietly been running for weeks. 🧬👀 $ARKG
4. Gene Editing’s Door
🚨 Gene editing just got the regulatory door it was built for.
FDA + CMS draft guidance: ONE application can cover multiple patient-specific variants of a gene-editing therapy.
Read that again. Ultra-rare diseases too small to trial one at a time just became a platform.
$PRME: IND cleared in September for Alpha-1, and it has now dosed the first patient in an in-body prime editing trial for Wilson’s disease. $BEAM: first clinical proof of concept for BEAM-301.
The market is starting to price platforms, not single drugs.
5. AI + Health
The AI labs are walking into the lab. Literally. 🧪
Anthropic bought a one-person biotech that ran on Claude. A new startup raised $215M for AI-run robotic labs. Formation Bio launched a $600M fund to push AI-found drugs through trials. $TWST signed with Lilly’s AI platform.
AI floods the pipeline with candidates. The new chokepoints are data and trials.
That’s where $TEM (the data), $ABCL (the discovery engine) and $TWST (the DNA it’s written in) sit.
Compute is revenue. Biology is the next customer. 👀
Not financial advice. Do your own research.
Originally posted on X by Rosanna Prestia, MBA (@RosannaInvests): https://x.com/RosannaInvests/status/2117634656904319193
